Citius Pharmaceuticals Inc vs Starbucks Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.72 (market cap $20.01M), while Starbucks Corp trades at $107.99 (market cap $121.59B). The key difference: Starbucks Corp is far larger — about 6076.5× Citius Pharmaceuticals Inc's market cap, and Starbucks Corp pays a 2.33% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | SBUX | |
|---|---|---|
Market Cap | $20.01M | $121.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $108.37 |
52-Week Low | $0.48 | $78.46 |
Enterprise Value | $16.23M | $140.42B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.33% |
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Starbucks (SBUX) trades at $107.57, up 2.79% today, showing strong momentum near its 52-week high. The stock benefits from a bullish technical outlook and improved quarterly earnings, with Q2 2026 EPS beating estimates at $0.85 vs. $0.66 expected. Revenue trends are positive, with 2025 revenue reaching $37.18B, though net income margin declined to 5.17%. Recent news highlights a turnaround in traffic and margin expansion, supported by new product launches like carbonated refreshers and seasonal offerings.
The outlook for SBUX is cautiously optimistic, with analyst consensus pointing to a $113.60 price target. Key opportunities include sustained traffic recovery and cost efficiency gains, but risks remain from high valuation (P/E 61.65) and competitive pressures. Investors should weigh the earnings rebound against premium multiples and monitor execution of growth initiatives.
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →